FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development
The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.

The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.
What are the risks of using generative AI systems like ChatGPT in medical practice, and who is ultimately held responsible for patient harm?
A neuroscientifically informed consumer confusion test for trademark infringement holds promise for reducing biases and manipulations.
By Matthew Chun In recent months, generative artificial intelligence (AI) has taken the world by storm. AI systems like ChatGPT and Stable Diffusion have captured the imagination of the masses with their impressive and sometimes controversial ability to generate human-like text and artwork. However, it may come as a surprise to some that — in…
Mapping the growth of U.S. innovation in the life sciences and computing fields from 1976-2021 through publicly available patent data.
“Drugs and the FDA” is a must-read for anyone interested in how the FDA became the trusted regulatory agency it is today.
As countries become more sensitive to the risks of sharing their citizens’ health data, international research collaborations will become more difficult.
Biden’s new initiative takes an expansive view of the roles of biotechnology and biomanufacturing in the United States economy.